The advancements in biotechnology and regenerative medicine, increasing prevalence of chronic diseases, and a rising demand for personalized medicine are factors driving the growth of the cell therapy market.
Innovative cell-based therapies that improve patient outcomes and treatment efficacy, such as CAR-T cell therapy, have attracted significant attention and investment. Cell therapies are also being validated by the growing number of research initiatives and clinical trials, while their approval processes are being expedited by supportive regulatory frameworks.
The growing awareness among healthcare providers and patients about the potential benefits of cell therapies is likely to bolster market expansion, alongside increasing healthcare expenditure and investments in research and development. As a result, the cell therapy market is projected to grow at a remarkable pace over the next decade.
Cell therapy is a novel approach in regenerative medicine that involves the administration of live cells to treat numerous diseases and conditions. This innovative therapy leverages the unique properties of cells to repair, replace, or regenerate damaged tissues and organs.
The development of cellular therapies initiates from finding appropriate cell sources, which can come from a variety of sources such as adult stem cells, induced pluripotent stem cells (iPSCs), and embryonic stem cells. To increase these cells' therapeutic potential, the procedure entails isolating them and, in certain situations, genetically altering them.
For instance, CAR-T (Chimeric Antigen Receptor T-cell) therapy is developed by extracting T cells from patient’s blood, followed by genetic engineering of the extracted cells to express specific receptors that target cancer cells, and then reintroduction of the modified cells into the patient to help eliminate tumors.
Cell therapy has applications in several therapeutic domains, including notable effects in orthopedics, cardiology, immunology, and oncology. CAR-T cell treatments have completely changed the way that some blood malignancies, such as non-Hodgkin lymphoma and acute lymphoblastic leukemia, are treated in oncology.
To improve T-cell infiltration and persistence in the tumor microenvironment, researchers are investigating cell treatments for solid tumors in addition to hematological malignancies. By reprogramming or replacing damaged immune cells, cell therapy is being used in immunology to treat autoimmune illnesses. This offers a new way to treat conditions including rheumatoid arthritis and multiple sclerosis.
| Attribute | Detail |
|---|---|
| Drivers |
|
The rising incidence of oncological disorders is a significant driver of growth in the cell therapy, as the demand for innovative and effective treatment options continues to escalate. Cancer remains one of the leading causes of morbidity and mortality worldwide, with millions of new cases diagnosed each year.
Traditional treatment modalities such as chemotherapy and radiation therapy often come with severe side-effects and limited efficacy, particularly in advanced stages of the disease. This has created a pressing need for novel therapeutic approaches that can more effectively target cancer cells while minimizing harm to healthy tissues. For instance, according to World Health Organization, in 2022, nearly 20.0 Mn new cancer cases and 9.7 Mn cancer deaths are recorded worldwide.
Cell therapies, particularly those involving immune cells like CAR-T (chimeric antigen receptor T-cell) therapies, have emerged as groundbreaking treatments for certain types of cancers. These therapies harness the body’s immune system to identify and destroy malignant cells, offering a personalized approach that can lead to improved outcomes for patients.
The success of CAR-T therapies in treating hematologic malignancies has sparked significant interest and investment in the development of similar therapies for solid tumors and the other cancer types.
Furthermore, advancements in biotechnology and genetic engineering are enhancing the potential of cell therapies. Techniques such as gene editing allow for the modification of immune cells to increase their effectiveness against specific cancer markers, thus broadening the applicability of these treatments.
The increase in financing and investments in the cell therapy market is a pivotal driver of its growth, reflecting a robust interest from both - public and private sectors to advanced innovative therapeutic solutions. Significant capital influxes are vital for research, development, and commercialization of cell therapies, which are often complex and expensive to produce.
For instance, in October 2023, Bayer AG invested US$ 250 Mn in a new cell therapy manufacturing facility in Berkeley, California, U.S. to produce materials for clinical trials and potential commercial launches of BlueRock Therapeutics' bemdaneprocel (BRT-DA01), an investigational cell therapy for Parkinson's Disease. Such substantial investments not only validate the potential of cell therapies but also stimulate further research and development efforts in the field.
Companies are able to improve manufacturing capacities, expedite clinical studies, and launch innovative treatments more quickly as financial support keeps increasing. In addition to encouraging research, this investment creates the infrastructure needed for the broad use of cell therapies, which will advance the industry and enhance the prognosis of patients with a variety of illnesses, most notably cancer.
The Cell therapy market segmentation based on cell therapy type includes T-cell therapy, stem cell therapy, natural killer cells, dendritic cells, and other cell therapies.
It is important to note that with the approval of CAR-T cell therapies such as Tecartus, Yescarta, and Kymriah, various entities have shifted their businesses model from the development of small molecule and protein-based treatments to adoptive therapies. This factor has increased strategic investments by private as well as public agencies in the arena resulting in boosting the market.
The rising product approval along with increasing manufacturing capacities are expected to increase the market competition in T-cell therapy entities in the forecast period. Further, the use of CAR-T therapies in the treatment of different cancers has increased as a result of improvements in their manufacturing.
Emergence of new strategies like second- and next-generation CAR-T immunotherapy can overcome challenges like resistance and adverse effects, increasing the generation of organic revenue.
According to the cell therapy market report, based on therapeutic area, the market is classified into Oncological Disorders, Autoimmune Disorders, Neurological Disorders and Others. The oncological disorders segment dominates the market.
The factors driving the market's growth include increasing patient assistance programs (PAPs), increasing government initiatives for cancer awareness, the rising prevalence of cancer worldwide, vital R&D initiatives from key players, and the increasing demand for personalized medicine.
For instance, in November 2023, the American Cancer Society introduced a new program, Community Access to Resources, Education, and Support (ACS CARES), which provides quality information and one-on-one support to cancer patients through the mobile application.
This program focuses on improving the accessibility of cancer care services to patients and caregivers by improving information. Thus, such initiatives may enhance the adoption of cancer therapy and contribute to the market's growth.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest cell therapy market analysis, North America dominated in 2023. Advancement of healthcare infrastructure, high investments in research, and augmented healthcare finances are driving market dynamics in the region.
The U.S.’ large market share in the North America cell therapy market is attributed to the advancement in healthcare infrastructure, increase in awareness, and augmented health care finances. Also, numerous cell therapy companies are based in the U.S.
Further, it is noteworthy that the European Union (EU) has increased funding for research and development in the life sciences, including cell therapy. The EU's Horizon 2020 program, for example, has allocated significant funds for regenerative medicine and cell therapy research.
European governments have implemented policies and initiatives to support the development of cell therapies. For example, the UK's Cell and Gene Therapy Catapult and the German government's "Cell and Gene Therapy" initiative provide funding, infrastructure, and regulatory support.
As cell therapy companies are constantly innovating to improve product efficacy, several therapies are being evaluated in clinical trials across the globe.
Novartis AG, Bristol-Myers Squibb Company, IOVANCE Biotherapeutics, Inc., Janssen Biotech, Inc., CellTrans, Inc., Gamida Cell Inc., Dendreon Pharmaceuticals LLC, Kite Pharma, Inc., Adaptimmune and Takeda Pharmaceutical Company Limited are the prominent cell therapy market players.
Each of these players has been have been profiled in the cell therapy market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2023 | US$ 4.8 Bn |
| Forecast Value in 2034 | More than US$ 44.6 Bn |
| CAGR | 20.8% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2023 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global cell therapy market was valued at US$ 4.8 Bn in 2023.
The cell therapy business is projected to reach more than US$ 44.6 Bn by the end of 2034.
The CAGR is anticipated to be 20.8% from 2024 to 2034.
Novartis AG, Bristol-Myers Squibb Company, IOVANCE Biotherapeutics, Inc., Janssen Biotech, Inc., CellTrans, Inc., Gamida Cell Inc., Dendreon Pharmaceuticals LLC, Kite Pharma, Inc., Adaptimmune, and Takeda Pharmaceutical Company Limited.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Cell Therapy Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cell Therapy Market Analysis and Forecasts, 2020-2034
5. Key Insights
5.1. Porter’s Five Forces Analysis
5.2. PEST Analysis
5.3. Key Industry Events - Product Approvals
5.4. Key Industry Events - Partnerships and Collaborations
6. Global Cell Therapy Market Analysis and Forecasts, By Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Type, 2020-2034
6.3.1. T-cell Therapy
6.3.1.1. Chimeric Antigen Receptor (CAR) T-cells
6.3.1.2. T-cell Receptors
6.3.1.3. Tumor-Infiltrating Lymphocytes
6.3.2. Stem Cell Therapy
6.3.3. Natural Killer Cells
6.3.4. Dendritic Cells
6.3.5. Other Cell Therapies
6.4. Market Attractiveness By Type
7. Global Cell Therapy Market Analysis and Forecasts, By Origin
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Origin, 2020-2034
7.3.1. Autologous Therapies
7.3.2. Allogenic Therapies
7.4. Market Attractiveness By Origin
8. Global Cell Therapy Market Analysis and Forecasts, By Therapeutic Area
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Therapeutic Area, 2020-2034
8.3.1. Oncological Disorders
8.3.2. Autoimmune Disorders
8.3.3. Neurological Disorders
8.3.4. Others
8.4. Market Attractiveness By Therapeutic Area
9. Global Cell Therapy Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Cell Therapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Type, 2020-2034
10.2.1. T-cell Therapy
10.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
10.2.1.2. T-cell Receptors
10.2.1.3. Tumor-Infiltrating Lymphocytes
10.2.2. Stem Cell Therapy
10.2.3. Natural Killer Cells
10.2.4. Dendritic Cells
10.2.5. Other Cell Therapies
10.3. Market Value Forecast By Origin, 2020-2034
10.3.1. Autologous Therapies
10.3.2. Allogenic Therapies
10.4. Market Value Forecast By Therapeutic Area, 2020-2034
10.4.1. Oncological Disorders
10.4.2. Autoimmune Disorders
10.4.3. Neurological Disorders
10.4.4. Others
10.5. Market Value Forecast By Country, 2020-2034
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Origin
10.6.3. By Therapeutic Area
10.6.4. By Country
11. Europe Cell Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Type, 2020-2034
11.2.1. T-cell Therapy
11.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
11.2.1.2. T-cell Receptors
11.2.1.3. Tumor-Infiltrating Lymphocytes
11.2.2. Stem Cell Therapy
11.2.3. Natural Killer Cells
11.2.4. Dendritic Cells
11.2.5. Other Cell Therapies
11.3. Market Value Forecast By Origin, 2020-2034
11.3.1. Autologous Therapies
11.3.2. Allogenic Therapies
11.4. Market Value Forecast By Therapeutic Area, 2020-2034
11.4.1. Oncological Disorders
11.4.2. Autoimmune Disorders
11.4.3. Neurological Disorders
11.4.4. Others
11.5. Market Value Forecast By Country/Sub-region, 2020-2034
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Origin
11.6.3. By Therapeutic Area
11.6.4. By Country/Sub-region
12. Asia Pacific Cell Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Type, 2020-2034
12.2.1. T-cell Therapy
12.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
12.2.1.2. T-cell Receptors
12.2.1.3. Tumor-Infiltrating Lymphocytes
12.2.2. Stem Cell Therapy
12.2.3. Natural Killer Cells
12.2.4. Dendritic Cells
12.2.5. Other Cell Therapies
12.3. Market Value Forecast By Origin, 2020-2034
12.3.1. Autologous Therapies
12.3.2. Allogenic Therapies
12.4. Market Value Forecast By Therapeutic Area, 2020-2034
12.4.1. Oncological Disorders
12.4.2. Autoimmune Disorders
12.4.3. Neurological Disorders
12.4.4. Others
12.5. Market Value Forecast By Country/Sub-region, 2020-2034
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Origin
12.6.3. By Therapeutic Area
12.6.4. By Country/Sub-region
13. Latin America Cell Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Type, 2020-2034
13.2.1. T-cell Therapy
13.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
13.2.1.2. T-cell Receptors
13.2.1.3. Tumor-Infiltrating Lymphocytes
13.2.2. Stem Cell Therapy
13.2.3. Natural Killer Cells
13.2.4. Dendritic Cells
13.2.5. Other Cell Therapies
13.3. Market Value Forecast By Origin, 2020-2034
13.3.1. Autologous Therapies
13.3.2. Allogenic Therapies
13.4. Market Value Forecast By Therapeutic Area, 2020-2034
13.4.1. Oncological Disorders
13.4.2. Autoimmune Disorders
13.4.3. Neurological Disorders
13.4.4. Others
13.5. Market Value Forecast By Country/Sub-region, 2020-2034
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Origin
13.6.3. By Therapeutic Area
13.6.4. By Country/Sub-region
14. Middle East & Africa Cell Therapy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Type, 2020-2034
14.2.1. T-cell Therapy
14.2.1.1. Chimeric Antigen Receptor (CAR) T-cells
14.2.1.2. T-cell Receptors
14.2.1.3. Tumor-Infiltrating Lymphocytes
14.2.2. Stem Cell Therapy
14.2.3. Natural Killer Cells
14.2.4. Dendritic Cells
14.2.5. Other Cell Therapies
14.3. Market Value Forecast By Origin, 2020-2034
14.3.1. Autologous Therapies
14.3.2. Allogenic Therapies
14.4. Market Value Forecast By Therapeutic Area, 2020-2034
14.4.1. Oncological Disorders
14.4.2. Autoimmune Disorders
14.4.3. Neurological Disorders
14.4.4. Others
14.5. Market Value Forecast By Country/Sub-region, 2020-2034
14.5.1. GCC
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Origin
14.6.3. By Therapeutic Area
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2023)
15.3. Company Profiles
15.3.1. Novartis AG
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Bristol-Myers Squibb Company
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. IOVANCE Biotherapeutics, Inc.
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. Janssen Biotech, Inc.
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. CellTrans, Inc.
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Gamida Cell Inc.
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. Dendreon Pharmaceuticals LLC
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Kite Pharma, Inc.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. Adaptimmune
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. Takeda Pharmaceutical Company Limited
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Business Strategies
15.3.10.5. Recent Developments
List of Tables
Table 01: Global Cell Therapy Market Value (US$ Mn) Forecast, by Type, 2020-2034
Table 02: Global Cell Therapy Market Value (US$ Mn) Forecast, by T-cell Therapy, 2020-2034
Table 03: Global Cell Therapy Market Value (US$ Mn) Forecast, by Origin, 2020-2034
Table 04: Global Cell Therapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 05: Global Cell Therapy Market Value (US$ Mn) Forecast, by Region, 2020-2034
Table 06: North America Cell Therapy Market Value (US$ Mn) Forecast, by Country, 2020-2034
Table 07: North America Cell Therapy Market Value (US$ Mn) Forecast, by Type, 2020-2034
Table 08: North America Cell Therapy Market Value (US$ Mn) Forecast, by T-cell Therapy, 2020-2034
Table 09: North America Cell Therapy Market Value (US$ Mn) Forecast, by Origin, 2020-2034
Table 10: North America Cell Therapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 11: Europe Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Europe Cell Therapy Market Value (US$ Mn) Forecast, by Type, 2020-2034
Table 13: Europe Cell Therapy Market Value (US$ Mn) Forecast, by T-cell Therapy, 2020-2034
Table 14: Europe Cell Therapy Market Value (US$ Mn) Forecast, by Origin, 2020-2034
Table 15: Europe Cell Therapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 16: Asia Pacific Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Asia Pacific Cell Therapy Market Value (US$ Mn) Forecast, by Type, 2020-2034
Table 18: Asia Pacific Cell Therapy Market Value (US$ Mn) Forecast, by T-cell Therapy, 2020-2034
Table 19: Asia Pacific Cell Therapy Market Value (US$ Mn) Forecast, by Origin, 2020-2034
Table 20: Asia Pacific Cell Therapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 21: Latin America Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Latin America Cell Therapy Market Value (US$ Mn) Forecast, by Type, 2020-2034
Table 23: Latin America Cell Therapy Market Value (US$ Mn) Forecast, by T-cell Therapy, 2020-2034
Table 24: Latin America Cell Therapy Market Value (US$ Mn) Forecast, by Origin, 2020-2034
Table 25: Latin America Cell Therapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
Table 26: Middle East & Africa Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Middle East & Africa Cell Therapy Market Value (US$ Mn) Forecast, by Type, 2020-2034
Table 28: Middle East & Africa Cell Therapy Market Value (US$ Mn) Forecast, by T-cell Therapy, 2020-2034
Table 29: Middle East & Africa Cell Therapy Market Value (US$ Mn) Forecast, by Origin, 2020-2034
Table 30: Middle East & Africa Cell Therapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2020-2034
List of Figures
Figure 01: Global Cell Therapy Market Value (US$ Mn) Share Analysis, by Type, 2023 and 2034
Figure 02: Global Cell Therapy Market Share Analysis, by Type, 2023
Figure 03: Global Cell Therapy Market Share Analysis, by Type, 2034
Figure 04: Global Cell Therapy Market Attractiveness Analysis, by Type, 2024-2034
Figure 05: Global Cell Therapy Market Value (US$ Mn), by T-cell Therapy, 2020-2034
Figure 06: Global Cell Therapy Market Value Share Analysis, by T-cell Therapy, 2024 and 2034
Figure 07: Global Cell Therapy Market Value (US$ Mn), by Stem Cell Therapy, 2020-2034
Figure 08: Global Cell Therapy Market Value Share Analysis, by Stem Cell Therapy, 2024 and 2034
Figure 09: Global Cell Therapy Market Value (US$ Mn), by Natural Killer Cells, 2020-2034
Figure 10: Global Cell Therapy Market Value Share Analysis, by Natural Killer Cells, 2024 and 2034
Figure 11: Global Cell Therapy Market Value (US$ Mn), by Dendritic Cells, 2020-2034
Figure 12: Global Cell Therapy Market Value Share Analysis, by Dendritic Cells, 2024 and 2034
Figure 13: Global Cell Therapy Market Value (US$ Mn), by Other Cell Therapies, 2020-2034
Figure 14: Global Cell Therapy Market Value Share Analysis, by Other Cell Therapies, 2024 and 2034
Figure 15: Global Cell Therapy Market Value (US$ Mn) Share Analysis, by Origin, 2023 and 2034
Figure 16: Global Cell Therapy Market Share Analysis, by Origin, 2023
Figure 17: Global Cell Therapy Market Share Analysis, by Origin, 2034
Figure 18: Global Cell Therapy Market Attractiveness Analysis, by Origin, 2024-2034
Figure 19: Global Cell Therapy Market Value (US$ Mn), by Autologous Therapies, 2020-2034
Figure 20: Global Cell Therapy Market Value Share Analysis, by Autologous Therapies, 2024 and 2034
Figure 21: Global Cell Therapy Market Value (US$ Mn), by Allogenic Therapies, 2020-2034
Figure 22: Global Cell Therapy Market Value Share Analysis, by Allogenic Therapies, 2024 and 2034
Figure 23: Global Cell Therapy Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 24: Global Cell Therapy Market Share Analysis, by Therapeutic Area, 2023
Figure 25: Global Cell Therapy Market Share Analysis, by Therapeutic Area, 2034
Figure 26: Global Cell Therapy Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
Figure 27: Global Cell Therapy Market Value (US$ Mn), by Oncological Disorders, 2020-2034
Figure 28: Global Cell Therapy Market Value Share Analysis, by Oncological Disorders, 2024 and 2034
Figure 29: Global Cell Therapy Market Value (US$ Mn), by Autoimmune Disorders, 2020-2034
Figure 30: Global Cell Therapy Market Value Share Analysis, by Autoimmune Disorders, 2024 and 2034
Figure 31: Global Cell Therapy Market Value (US$ Mn), by Neurological Disorders, 2020-2034
Figure 32: Global Cell Therapy Market Value Share Analysis, by Neurological Disorders, 2024 and 2034
Figure 33: Global Cell Therapy Market Value (US$ Mn), by Others, 2020-2034
Figure 34: Global Cell Therapy Market Value Share Analysis, by Others, 2024 and 2034
Figure 35: Global Cell Therapy Market Value Share Analysis, by Region, 2023 and 2034
Figure 36: Global Cell Therapy Market Share Analysis, by Region, 2023
Figure 37: Global Cell Therapy Market Share Analysis, by Region, 2034
Figure 38: Global Cell Therapy Market Attractiveness Analysis, by Region, 2024-2034
Figure 39: North America Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 40: North America Cell Therapy Market Value Share Analysis, by Country, 2023 and 2034
Figure 41: North America Cell Therapy Market Attractiveness Analysis, by Country, 2024-2034
Figure 42: North America Cell Therapy Market Value (US$ Mn) Share Analysis, by Type, 2023 and 2034
Figure 43: North America Cell Therapy Market Attractiveness Analysis, by Type, 2024-2034
Figure 44: North America Cell Therapy Market Value (US$ Mn) Share Analysis, by Origin, 2023 and 2034
Figure 45: North America Cell Therapy Market Share Analysis, by Origin, 2023
Figure 46: North America Cell Therapy Market Share Analysis, by Origin, 2034
Figure 47: North America Cell Therapy Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 48: North America Cell Therapy Market Share Analysis, by Therapeutic Area, 2023
Figure 49: North America Cell Therapy Market Share Analysis, by Therapeutic Area, 2034
Figure 50: Europe Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 51: Europe Cell Therapy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 52: Europe Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 53: Europe Cell Therapy Market Value (US$ Mn) Share Analysis, by Type, 2023 and 2034
Figure 54: Europe Cell Therapy Market Attractiveness Analysis, by Type, 2024-2034
Figure 55: Europe Cell Therapy Market Value (US$ Mn) Share Analysis, by Origin, 2023 and 2034
Figure 56: Europe Cell Therapy Market Share Analysis, by Origin, 2023
Figure 57: Europe Cell Therapy Market Share Analysis, by Origin, 2034
Figure 58: Europe Cell Therapy Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 59: Europe Cell Therapy Market Share Analysis, by Therapeutic Area, 2023
Figure 60: Europe Cell Therapy Market Share Analysis, by Therapeutic Area, 2034
Figure 61: Asia Pacific Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 62: Asia Pacific Cell Therapy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 63: Asia Pacific Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 64: Asia Pacific Cell Therapy Market Value (US$ Mn) Share Analysis, by Type, 2023 and 2034
Figure 65: Asia Pacific Cell Therapy Market Attractiveness Analysis, by Type, 2024-2034
Figure 66: Asia Pacific Cell Therapy Market Value (US$ Mn) Share Analysis, by Origin, 2023 and 2034
Figure 67: Asia Pacific Cell Therapy Market Share Analysis, by Origin, 2023
Figure 68: North America Cell Therapy Market Share Analysis, by Origin, 2034
Figure 69: Asia Pacific Cell Therapy Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 70: Asia Pacific Cell Therapy Market Share Analysis, by Therapeutic Area, 2023
Figure 71: Asia Pacific Cell Therapy Market Share Analysis, by Therapeutic Area, 2034
Figure 72: Latin America Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 73: Latin America Cell Therapy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 74: Latin America Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 75: Latin America Cell Therapy Market Value (US$ Mn) Share Analysis, by Type, 2023 and 2034
Figure 76: Latin America Cell Therapy Market Attractiveness Analysis, by Type, 2024-2034
Figure 77: Latin America Cell Therapy Market Value (US$ Mn) Share Analysis, by Origin, 2023 and 2034
Figure 78: Latin America Cell Therapy Market Attractiveness Analysis, by Origin, 2024-2034
Figure 79: Latin America Cell Therapy Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 80: Latin America Cell Therapy Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
Figure 81: Middle East & Africa Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 82: Middle East & Africa Cell Therapy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 83: Middle East & Africa Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 84: Middle East & Africa Cell Therapy Market Value (US$ Mn) Share Analysis, by Type, 2023 and 2034
Figure 85: Middle East & Africa Cell Therapy Market Attractiveness Analysis, by Type, 2024-2034
Figure 86: Middle East & Africa Cell Therapy Market Value (US$ Mn) Share Analysis, by Origin, 2023 and 2034
Figure 87: Middle East & Africa Cell Therapy Market Attractiveness Analysis, by Origin, 2024-2034
Figure 88: Middle East & Africa Cell Therapy Market Value (US$ Mn) Share Analysis, by Therapeutic Area, 2023 and 2034
Figure 89: Middle East & Africa Cell Therapy Market Attractiveness Analysis, by Therapeutic Area, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cell Therapy Market
